ESCRS - PP08.07 - Comparative Analysis Of Visual Outcomes With Tecnis Puresee And Eyhance

Comparative Analysis Of Visual Outcomes With Tecnis Puresee And Eyhance

Published 2025 - 43rd Congress of the ESCRS

Reference: PP08.07 | Type: Free paper | DOI: 10.82333/dk7c-9217

Authors: Lia Clara Margherita Agliati* 1 , Arianna Paris 1 , Matteo Bonanata 1 , Arianna Peyla 1 , Michele Clerici 1 , Gabriela Grimaldi 1 , Lucas Bachmann 2 , Moreno Menghini 1

1Ophthalmology,Ente ospedaliero cantonale,Lugano,Switzerland, 2University of Zuerich,Zürich,Switzerland;Medignition Inc. Research Consultants Zurich,Zürich,Switzerland

Purpose

To compare visual and refractive outcomes of two intraocular lens models (IOLs): Tecnis PureSee/PureSee toric (a new partial range of field extended (PRoF-Ex) IOL with the more established Eyhance/Eyhance toric IOL (partial range of field  enhanced (PRoF-En) IOL.  

Setting

Optegra Eye Health Care, UK a private eye hospital group.

Methods

Retrospective audit of outcomes data from 1355 eyes following phacoemulsification between January 2024 and December 2025. N=656 (50% toric) implantations were PureSee and N=699 (86% toric) were Eyhance.  Data were extracted from the electronic medical record and exported for analysis. 

Results

Mean age was 65 ± 10 years in the Puresee group and 72 ± 10 years old in the Eyhance group (p>0.05). The percentage of eyes achieving UDVA 6/6 or better was higher in the PureSee (54%) vs. Eyhance (44%) group in this cohort, Mann Whitney U test (MWUT) p <0.05. The % of eyes achieving N8 or better was significantly higher for PureSee (74%) compared to Eyhance (55%) p<0.05. For refractive predictability 93% and 63% of PureSee eyes were within 1D and 0.50D of predicted post operative refraction and 96% and 82% of Eyhance eyes were within these metrics.  

Conclusions

Our data show that the newer PureSee IOL demonstrated good visual outcomes at distance and near and compared favourably to  Eyhance. It is expected that IOL constant optimisation refinement will further improve refractive outcome for the newer PRoF-extended IOL.